Combined small‐cell lung carcinoma: An institutional experience

Thoracic Cancer

Audrey S. Wallace²  Monika Arya⁴  Shellaine R. Frazier³  Steven Westgate¹  Zhenyu Wang⁵ 

[1]Department of Radiology, University of Missouri, School of Medicine, Columbia, MO, USA

[2]University of Missouri, School of Medicine, Columbia, MO, USA

[3]Department of Pathology and Anatomical Science, University of Missouri, School of Medicine, Columbia, MO, USA

[4]Division of Hematology and Medical Oncology, University of Missouri, School of Medicine, Columbia, MO, USA

[5]Department of Statistics, University of Missouri, Columbia, MO, USA

关键词: Chemotherapy;    combined‐histology;    outcome;    radiotherapy;    small cell lung cancer;   

DOI  :  10.1111/1759-7714.12059

来源: Wiley

【 摘 要 】

Abstract

Background

The purpose of this study is to determine prognostic factors and survival in patients who present with combined small-cell lung cancer (SCLC).

Methods

A retrospective review of combined SCLC histology in patients treated between1995–2010 was undertaken. Demographics, diagnostic information, disease characteristics, treatment modality, and survival were captured. Survival estimates were performed using Kaplan Meier analysis. Statistical significance was defined as P < 0.05.

Results

Forty-one patients were identified, and 35 records were available for analysis. Median age at diagnosis was 68 (range 50–85). The study included 20 (57%) women and 15 (43%) men; and 94% had a current or former history of smoking. Histology was SCLC/large cell carcinoma not otherwise specified in 28 (80%), and SCLC/adenocarcinoma or SCLC/squamous cell carcinoma in seven (20%). Cardiac or pulmonary comorbidities were present in 80% of patients, and 24 patients had metastatic disease at presentation. Twenty-eight patients received treatment of chemotherapy (n = 24), cranial radiotherapy (n = 5), or thoracic radiotherapy (n = 7). Staging was as follows: stage I-III (n = 11), stage IV (n = 24). Median survival was 15.4 months (range <1–53 months) and 3.4 months (range <1–21.9 months) for American Joint Committee on Cancer (AJCC) stage I-III and stage IV, respectively. Estimated overall six and 12 month survival was 82%, 55%, 37%, and 17% for stage I-III and stage IV, respectively. An improved overall survival rate was found for patients with an Eastern Cooperative Oncology Group performance status of <2, and no weight loss (P < 0.05).

Conclusion

Akin to SCLC, advanced stage combined SCLC portends a poor prognosis. Perhaps novel chemotherapeutic drugs or targeted agents may improve outcomes for future patient populations.

【 授权许可】

Unknown   
© 2013 Tianjin Lung Cancer Institute and Wiley Publishing Asia Pty Ltd